Neshanth Easwaralingam
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Neshanth Easwaralingam has a total of 39 co-authors. Here are the top co-authors by number of shared publications:
- Chu Luan Nguyen
Department of Breast Surgery, Chris O’Brien Lifehouse, Camperdown, Australia
4 shared publications Cindy Mak
Department of Breast Surgery, Chris O’Brien Lifehouse , Sydney, New South Wales
4 shared publicationsFarhad Azimi
Department of Breast Surgery, Chris O’Brien Lifehouse , Sydney, New South Wales
3 shared publicationsSanjay Warrier
Department of Breast Surgery, Chris O’Brien Lifehouse , Sydney, New South Wales
3 shared publications- Alexander Peter Comerford
Department of Surgery The University of Sydney Sydney New South Wales Australia
2 shared publications Belinda Chan
Department of Breast Surgery, Chris O’Brien Lifehouse , Sydney, New South Wales
2 shared publications
Latest Publications
- Open Access
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Indocyanine green versus technetium-99m for sentinel lymph node biopsy in breast cancer: the FLUORO trial
Background: Standard sentinel lymph node (SLN) mapping for early breast cancer involves technetium-99m (99mTc) lymphoscintigraphy. Indocyanine green (ICG) fluorescence allows real-time visualization of lymphatics and nodes while avoiding radiation exposure and the inconvenience of 99mTc, but its inclusion in international guidelines is not widespread. This study compared efficacy and costs between ICG and 99mTc for axillary SLN lymphatic mapping. Methods: Patients with early breast cancer and clinically negative axilla who underwent lymphatic mapping with ICG and 99mTc were enrolled in a prospective single-institution single-arm non-randomized trial (2021–2024). Data on the number of SLNs, including metastatic nodes, rate of failed mapping, costs, and the surgeon’s reported ease of mapping with ICG compared with 99mTc were collected. Cost analysis used Medicare item numbers and microcosting. Results: A total of 305 patients were enrolled, with 637 SLNs sampled. The SLN identification rate was 97.8% (95% confidence interval (c.i.) 96.3 to 98.7%) for ICG and 98.3% (95% c.i. 96.9 to 99%) for 99mTc. The mean(standard deviation (s.d.)) number of SLNs identified with ICG and 99mTc was 2.06 (1.99) and 2.07 (2.02), respectively (P = 0.871). Metastatic SLNs were identified in 70 of 305 patients (23.0%), with 83 metastatic SLNs in total. ICG identified 79 of 83 metastatic SLNs (95.2%; 95% c.i. 88.3 to 98.1%) and 99mTc identified 82 of 83 metastatic SLNs (98.8%; 95% c.i. 93.5 to 99.8%; P = 0.256). Mean(s.d.) surgeon-reported ease for using ICG and 99mTc, rated used a five-point Likert scale, was 1.67 (0.98) (95% c.i. 1.56 to 1.78) and 1.5 (0.59) (95% c.i. 1.43 to 1.57), respectively (P = 0.082). 99mTc cost an additional EUR841 (95% c.i. EUR766 to EUR917) per patient but ICG would require > 35 patients before breaking even with initial outlay equipment costs. Conclusion: ICG fluorescence performed similarly to 99mTc lymphoscintigraphy and may be less costly over the long term.
- 8 September 2025
- Published by Oxford University Press (OUP) in BJS Open
- Vol. 9 (5)
Open AccessIndocyanine green versus technetium-99m for sentinel lymph node biopsy in breast cancer: the FLUORO trial
Background: Standard sentinel lymph node (SLN) mapping for early breast cancer involves technetium-99m (99mTc) lymphoscintigraphy. Indocyanine green (ICG) fluorescence allows real-time visualization of lymphatics and nodes while avoiding radiation exposure and the inconvenience of 99mTc, but its inclusion in international guidelines is not widespread. This study compared efficacy and costs between ICG and 99mTc for axillary SLN lymphatic mapping. Methods: Patients with early breast cancer and clinically negative axilla who underwent lymphatic mapping with ICG and 99mTc were enrolled in a prospective single-institution single-arm non-randomized trial (2021–2024). Data on the number of SLNs, including metastatic nodes, rate of failed mapping, costs, and the surgeon’s reported ease of mapping with ICG compared with 99mTc were collected. Cost analysis used Medicare item numbers and microcosting. Results: A total of 305 patients were enrolled, with 637 SLNs sampled. The SLN identification rate was 97.8% (95% confidence interval (c.i.) 96.3 to 98.7%) for ICG and 98.3% (95% c.i. 96.9 to 99%) for 99mTc. The mean(standard deviation (s.d.)) number of SLNs identified with ICG and 99mTc was 2.06 (1.99) and 2.07 (2.02), respectively (P = 0.871). Metastatic SLNs were identified in 70 of 305 patients (23.0%), with 83 metastatic SLNs in total. ICG identified 79 of 83 metastatic SLNs (95.2%; 95% c.i. 88.3 to 98.1%) and 99mTc identified 82 of 83 metastatic SLNs (98.8%; 95% c.i. 93.5 to 99.8%; P = 0.256). Mean(s.d.) surgeon-reported ease for using ICG and 99mTc, rated used a five-point Likert scale, was 1.67 (0.98) (95% c.i. 1.56 to 1.78) and 1.5 (0.59) (95% c.i. 1.43 to 1.57), respectively (P = 0.082). 99mTc cost an additional EUR841 (95% c.i. EUR766 to EUR917) per patient but ICG would require > 35 patients before breaking even with initial outlay equipment costs. Conclusion: ICG fluorescence performed similarly to 99mTc lymphoscintigraphy and may be less costly over the long term.
- Open Access
- 13 May 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 94 (6) , 1083-1089
Radar localization of breast and axillary lesions with SCOUT: a prospective single institution pilot study
Background: Wire-guided localization has been the mainstay of localization techniques for non-palpable breast and axillary lesions prior to excision. Evidence is still growing for relatively newer localization technologies. This study evaluated the efficacy of the wireless localization technology, SCOUT (R), for both breast and axillary surgery. Methods: Data were extracted from a prospective database (2021-2023) of consecutive patients undergoing wide local excision, excisional biopsy, targeted axillary dissection, or axillary lymph node dissection with SCOUT at a high-volume tertiary centre. Rates of successful reflector placement, intraoperative lesion localization, and reflector retrieval were evaluated. A survey of surgeon-reported ease of lesion localization and reflector retrieval was also evaluated. Clinical trial registration: ACTRN386751. Results: One-hundred-ninety-five reflectors were deployed in 172 patients. Median interval between deployment and surgery was 3 days (range 1-20) and mean distance from reflector to lesion was 3.2 mm (standard deviation, SD 3.1). Rate of successful localization and reflector retrieval was 100% for both breast and axillary procedures. Mean operating time was 65.8 min (SD 33). None of the reflectors migrated. No reflector deployment or localization-related complications occurred. Ninety-eight percent of surgeons were satisfied with ease of localization for the first half of cases. Conclusion: SCOUT is an accurate and reliable method to localize and excise both breast and axillary lesions, and it may overcome some of the limitations of wire-guided localization.
- 13 May 2024
- Published by Wiley in Anz Journal of Surgery
- Vol. 94 (6) , 1083-1089
Open AccessRadar localization of breast and axillary lesions with SCOUT: a prospective single institution pilot study
Background: Wire-guided localization has been the mainstay of localization techniques for non-palpable breast and axillary lesions prior to excision. Evidence is still growing for relatively newer localization technologies. This study evaluated the efficacy of the wireless localization technology, SCOUT (R), for both breast and axillary surgery. Methods: Data were extracted from a prospective database (2021-2023) of consecutive patients undergoing wide local excision, excisional biopsy, targeted axillary dissection, or axillary lymph node dissection with SCOUT at a high-volume tertiary centre. Rates of successful reflector placement, intraoperative lesion localization, and reflector retrieval were evaluated. A survey of surgeon-reported ease of lesion localization and reflector retrieval was also evaluated. Clinical trial registration: ACTRN386751. Results: One-hundred-ninety-five reflectors were deployed in 172 patients. Median interval between deployment and surgery was 3 days (range 1-20) and mean distance from reflector to lesion was 3.2 mm (standard deviation, SD 3.1). Rate of successful localization and reflector retrieval was 100% for both breast and axillary procedures. Mean operating time was 65.8 min (SD 33). None of the reflectors migrated. No reflector deployment or localization-related complications occurred. Ninety-eight percent of surgeons were satisfied with ease of localization for the first half of cases. Conclusion: SCOUT is an accurate and reliable method to localize and excise both breast and axillary lesions, and it may overcome some of the limitations of wire-guided localization.
- Open Access
- 28 December 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (1-2) , 270-275
Trends in outcomes with adoption of indocyanine green angiography in postmastectomy reconstruction
BackgroundIndocyanine green angiography (ICGA) aims to reduce ischaemic complications by supplementing intraoperative perfusion assessment of mastectomy flaps. Learning curves for this technology have not been analysed. We evaluated changes in patient outcomes with increasing case volume after ICGA adoption in postmastectomy reconstruction. MethodsSingle-institution retrospective analysis of 320 implant-based reconstructions following mastectomy using ICGA from 2015, when it was introduced, to 2021. Cases chronologically divided into tertiles and complications amongst groups evaluated. Trends in ischaemic complications plotted using weighted moving average. CUSUM analysis determined after how many cases plateau was reached. Number of ischaemic complications prior to plateau calculated with AUC analysis. ResultsIschaemic complications decreased over time (Group 1, 15.1%; Group 2, 11.2%; Group 3, 4.7%, P = 0.034). Cases of delayed reconstruction increased over time (Group 1, 6.6%; Group 2, 28%; Group 3, 22.4%; P < 0.001). Our institution reached plateau of 10% ischaemic complications after 160 cases. Mean incidence of ischaemic complications decreased from 16.9% during the first 160 cases to 3.8% after plateau was reached (P < 0.001). Eleven extra breasts (6.9%) experienced ischaemic complications, that may have been avoided if operated by surgeons after the first 160 cases. ConclusionsThere was increased tendency towards a conservative approach of delaying reconstruction and decreased rates of ischaemic complications with increasing case volume after ICGA implementation. A significant number of cases were needed to reach plateau of minimal ischaemic complications. This data could encourage development of standardized protocols for this technology to shorten learning curves for improved patient outcomes.
- 28 December 2022
- Published by Wiley in Anz Journal of Surgery
- Vol. 93 (1-2) , 270-275
Open AccessTrends in outcomes with adoption of indocyanine green angiography in postmastectomy reconstruction
BackgroundIndocyanine green angiography (ICGA) aims to reduce ischaemic complications by supplementing intraoperative perfusion assessment of mastectomy flaps. Learning curves for this technology have not been analysed. We evaluated changes in patient outcomes with increasing case volume after ICGA adoption in postmastectomy reconstruction. MethodsSingle-institution retrospective analysis of 320 implant-based reconstructions following mastectomy using ICGA from 2015, when it was introduced, to 2021. Cases chronologically divided into tertiles and complications amongst groups evaluated. Trends in ischaemic complications plotted using weighted moving average. CUSUM analysis determined after how many cases plateau was reached. Number of ischaemic complications prior to plateau calculated with AUC analysis. ResultsIschaemic complications decreased over time (Group 1, 15.1%; Group 2, 11.2%; Group 3, 4.7%, P = 0.034). Cases of delayed reconstruction increased over time (Group 1, 6.6%; Group 2, 28%; Group 3, 22.4%; P < 0.001). Our institution reached plateau of 10% ischaemic complications after 160 cases. Mean incidence of ischaemic complications decreased from 16.9% during the first 160 cases to 3.8% after plateau was reached (P < 0.001). Eleven extra breasts (6.9%) experienced ischaemic complications, that may have been avoided if operated by surgeons after the first 160 cases. ConclusionsThere was increased tendency towards a conservative approach of delaying reconstruction and decreased rates of ischaemic complications with increasing case volume after ICGA implementation. A significant number of cases were needed to reach plateau of minimal ischaemic complications. This data could encourage development of standardized protocols for this technology to shorten learning curves for improved patient outcomes.
- 27 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (9) , 3014-3021
Cost-effectiveness of indocyanine green angiography in postmastectomy breast reconstruction
- 27 April 2022
- Published by Elsevier in Journal of Plastic, Reconstructive & Aesthetic Surgery
- Vol. 75 (9) , 3014-3021
Cost-effectiveness of indocyanine green angiography in postmastectomy breast reconstruction
- Open Access
- 1 June 2021
- Published by AME Publishing Company in Annals of Breast Surgery
- Vol. 5, 17
Acellular dermal matrices in breast reconstruction: a narrative review and institutional perspective
Breast reconstruction after mastectomy is commonly undertaken in patients inappropriate for breast conserving surgery, women who are at high genetic risk for breast cancer or otherwise based on patient preference. Current breast reconstruction techniques are diverse and may involve the use of an autologous tissue flap, tissue expanders or definitive implants. Regardless of the technique used, the use of acellular dermal matrices (ADMs) has become increasingly prevalent. The increased uptake of ADMs has led to a paradigm shift in breast reconstruction. This has led to a proliferation of new products and materially contributed to increased rates of pre-pectoral reconstruction. Single-stage and two-stage breast reconstruction remain a contentious issue with increasing evidence justifying direct-to-implant reconstruction in well selected patients with ADMs. ADMs are able to provide solutions to a multitude of issues surrounding inadequate tissue coverage and support, such as implant rippling, implant migration and capsular contracture. This review outlines an overview of the history of ADMs, commonly used ADMs and addresses the evidence with respect to known complications of ADMs. A number of product alternatives to ADMs are explored and an analysis of materials and characteristics are also provided. Notwithstanding cheaper costs of manufacturing these products may offer comparable outcomes. Ultimately this narrative review provides an institutional insight into breast reconstruction in a high volume Australian centre routinely employing ADMs. Important adjuncts such as indocyanine green angiography (ICGA) and negative pressure wound therapy (NPWT) have enhanced outcomes in our practice facilitating the identification of patients likely to benefit from staged expander based reconstruction.
- 1 June 2021
- Published by AME Publishing Company in Annals of Breast Surgery
- Vol. 5, 17
Open AccessAcellular dermal matrices in breast reconstruction: a narrative review and institutional perspective
Breast reconstruction after mastectomy is commonly undertaken in patients inappropriate for breast conserving surgery, women who are at high genetic risk for breast cancer or otherwise based on patient preference. Current breast reconstruction techniques are diverse and may involve the use of an autologous tissue flap, tissue expanders or definitive implants. Regardless of the technique used, the use of acellular dermal matrices (ADMs) has become increasingly prevalent. The increased uptake of ADMs has led to a paradigm shift in breast reconstruction. This has led to a proliferation of new products and materially contributed to increased rates of pre-pectoral reconstruction. Single-stage and two-stage breast reconstruction remain a contentious issue with increasing evidence justifying direct-to-implant reconstruction in well selected patients with ADMs. ADMs are able to provide solutions to a multitude of issues surrounding inadequate tissue coverage and support, such as implant rippling, implant migration and capsular contracture. This review outlines an overview of the history of ADMs, commonly used ADMs and addresses the evidence with respect to known complications of ADMs. A number of product alternatives to ADMs are explored and an analysis of materials and characteristics are also provided. Notwithstanding cheaper costs of manufacturing these products may offer comparable outcomes. Ultimately this narrative review provides an institutional insight into breast reconstruction in a high volume Australian centre routinely employing ADMs. Important adjuncts such as indocyanine green angiography (ICGA) and negative pressure wound therapy (NPWT) have enhanced outcomes in our practice facilitating the identification of patients likely to benefit from staged expander based reconstruction.
- 26 November 2019
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (1-2) , 34-40
Window of opportunity treatment in breast cancer
Window of opportunity therapies, which involve short‐term administration of systemic therapy between cancer diagnosis and surgery, have raised significant interest in recent years as a mean of assessing the sensitivity of a patient's cancer to therapy prior to surgery. There is now compelling evidence that in patients with early stage hormone‐receptor positive breast cancer, a 2‐week preoperative treatment with standard hormone therapies in a preoperative window period provides important prognostic information, which in turn helps to aid decision‐making regarding treatment options. Changes in short‐term biomarker endpoints such as cell proliferation measured by Ki‐67 can act as surrogate markers of long‐term outcomes. Paired tissues obtained pre‐ and post‐investigational treatment, without having to subject the patient to additional biopsies, can then be used to conduct translational research to investigate predictive biomarkers and pharmacodynamics. In this review, we will examine the utility and challenges of window of opportunities therapies in breast cancer in the current literature, and the current Australian and international trial landscape in this clinical space.
- 26 November 2019
- Published by Wiley in Anz Journal of Surgery
- Vol. 90 (1-2) , 34-40
Window of opportunity treatment in breast cancer
Window of opportunity therapies, which involve short‐term administration of systemic therapy between cancer diagnosis and surgery, have raised significant interest in recent years as a mean of assessing the sensitivity of a patient's cancer to therapy prior to surgery. There is now compelling evidence that in patients with early stage hormone‐receptor positive breast cancer, a 2‐week preoperative treatment with standard hormone therapies in a preoperative window period provides important prognostic information, which in turn helps to aid decision‐making regarding treatment options. Changes in short‐term biomarker endpoints such as cell proliferation measured by Ki‐67 can act as surrogate markers of long‐term outcomes. Paired tissues obtained pre‐ and post‐investigational treatment, without having to subject the patient to additional biopsies, can then be used to conduct translational research to investigate predictive biomarkers and pharmacodynamics. In this review, we will examine the utility and challenges of window of opportunities therapies in breast cancer in the current literature, and the current Australian and international trial landscape in this clinical space.
- Open Access
- 1 November 2018
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2018 (11) , rjy317
Radiotherapy for breast cancer associated with a cutaneous presentation of systemic mastocytosis—a case report and literature review
Ionizing radiation therapy is a common adjuvant therapy for individuals undergoing surgery for breast cancer. There are many well-recognized acute and chronic cutaneous reactions that can vary in severity, course and duration. We present a rare cutaneous manifestation of systemic mastocystosis, in a 59-year-old female who underwent adjuvant radiotherapy following local excision of ductal carcinoma in situ.
- 1 November 2018
- Published by Oxford University Press (OUP) in Journal of Surgical Case Reports
- Vol. 2018 (11) , rjy317
Open AccessRadiotherapy for breast cancer associated with a cutaneous presentation of systemic mastocytosis—a case report and literature review
Ionizing radiation therapy is a common adjuvant therapy for individuals undergoing surgery for breast cancer. There are many well-recognized acute and chronic cutaneous reactions that can vary in severity, course and duration. We present a rare cutaneous manifestation of systemic mastocystosis, in a 59-year-old female who underwent adjuvant radiotherapy following local excision of ductal carcinoma in situ.